Here are the stocks added to the Zacks #5 Rank ("strong sell") List today:

1-800-FLOWERS.COM Inc (FLWS) 3D Systems Corp (TDSC) ACI Worldwide Inc (ACIW) Advanta Corp (ADVNB) Alon USA Energy Inc (ALJ) Alphatec Holdings Inc (ATEC) American Water Works Co Inc (AWK) AMETEK Inc (AME) Anaren Inc (ANEN) Animal Health International Inc (AHII) Apogee Enterprises Inc (APOG) Bankrate Inc (RATE) Banner Corp (BANR) Bel Fuse Inc (BELFB) Belden Inc (BDC) Bio-Rad Laboratories Inc (BIO) Blockbuster Inc (BBI) ...

For Immediate Release

Chicago, IL - April 17, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Infinity Pharmaceuticals Inc (INFI), Novartis (NVS), Pfizer (PFE), OmniVision Technologies Inc (OVTI) and Google (GOOG).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

Infinity's RING Trial Halted

Yesterday, Infinity Pharmaceuticals Inc (INFI) announced the termination of its phase III RING trial based on the recommendation of its independent data monitoring committee (IDMC). The RING trial is a randomized, double-blind, placebo-controlled study designed to evaluate IPI-504, a Hsp90 inhibitor,

...

Infinity Pharmaceuticals, Inc. (NASD: INFI), an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions, recently announced that the company has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926. The Phase 1 trial is an open-label, dose-escalation study evaluating IPI-926 in up to 50 patients with advanced and/or metastatic solid tumors.

IPI-926 is a proprietary inhibitor of the Hedgehog signaling pathway that binds to and inhibits a key regulator of this pathway, the Smoothened receptor. The Hedgehog signaling pathway is normally active in regulating tissue and organ formation during embryonic development. Abnormal activation of the Hedgehog pathway can lead to cancer and is believed to play a central role in allowing the proliferation and survival of several types of cancers, including pancreatic, prostate, lung, breast, and certain brain cancers.

...